ARTIELLE

Artielle Immunotherapeutics is a clinical stage, venture-backed company headquartered in Portland, OR. Artielle is developing a novel, first-in-class platform of biologic drugs to treat a range of inflammatory and degenerative diseases. The company recently completed Phase I safety studies with its lead compound, RTL1000, in patients with MS and is preparing to initiate Phase I/II trials in the coming months.

Also known as: Artielle Immunotherapeutics, Artielle ImmunoTherapeutics, Inc.

Primary location: Tigard United States